Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Oncotargets and Therapy|August 18, 2020
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three CasesLijun Du, Lei Zhang, Ling Li, et al.
Therapeutic Advances in Medical Oncology|June 20, 2020
Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) <i>versus</i> CHOP in newly diagnosed peripheral T-cell lymphoma patientsYuanyuan Sun, Ling Li, Xin Li, et al.
International Journal of Cancer|October 9, 2020
Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter studyLei Zhang, Yan Wang, Xin Li, et al.
Journal of Hematology & Oncology|February 2, 2018
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphomaXin Li, Yasong Cheng, Mingzhi Zhang, et al.
Journal of Cancer Research and Clinical Oncology|July 20, 2022
The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphomaZhenchang Sun, Wenjuan Wan, Xudong Zhang, et al.
Molecular Medicine (Cambridge, Mass.)|August 24, 2018
AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphomaJiaqin Yan, Junhui Zhang, Xudong Zhang, et al.
Experimental Cell Research|December 27, 2017
SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphomaJiaqin Yan, Junhui Zhang, Xudong Zhang, et al.
Cancer Management and Research|February 28, 2019
Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with <i>MYC</i>, <i>BCL2/BCL6</i> gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical studyQianwen Ma, Yu Chang, Ling Li, et al.
Cancer|January 4, 2026
A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphomaWanyue Zhao, Ling Li, Xiaorui Fu, et al.
Leukemia & Lymphoma|February 14, 2015
Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphomaYingying Cui, Xin Li, Zhenchang Sun, et al.
Pageof 10